Beating Tissue Failure in Oncology - Takeaways - MDSpire

Beating Tissue Failure in Oncology

  • By

  • Helen Bristow

  • June 4, 2026

Share

  • 1

    Imagenomix aims to enhance access to precision medicine using an AI-powered platform that analyzes standard H&E slides for molecular signals.

  • 2

    In the US, 25% of oncology cases exhaust biopsy tissue before molecular characterization, leading to missed opportunities for mutation testing.

  • 3

    AI prescreening can significantly reduce costs and time to treatment by identifying high-probability mutations before expensive confirmatory tests.

  • 4

    The Imagenomix platform can improve clinical trial efficiency by screening candidates and preserving tissue for molecular testing.

  • 5

    Preliminary studies indicate that Imagenomix's assays for lung and breast cancer mutations are on track for launch in late 2026.

Original Source(s)

Beating Tissue Failure in Oncology

  • by Helen Bristow

  • June 4, 2026

Related Content

Benchmarking Large Language Models and Prompt Engineering Strategies in Microsatellite Instability Cancers: Evaluation Study

Why We Made a Mobile Digital Pathology Lab

Todd R. Minnigh and his team created ScanVan to address a problem with rare cancer diagnosis that had a particularly personal significance

DeepInsight-Net: a CBAM-enhanced ResNet50 framework with focal loss for robust cervical cancer classification on multi-center datasets